Tailoring CKD Management to Cardiovascular Risk and Multidisciplinary Monitoring

In ‘Tailoring CKD Management to Cardiovascular Risk and Multidisciplinary Monitoring,’ our experts delve into the following critical questions:

1. How does the management strategy for patients with CKD and T2D change based on their cardiovascular risk profile?
2. How do cardiology and nephrology perspectives differ in monitoring therapeutic response in CKD, particularly with respect to reliance on eGFR alone versus combined eGFR and uACR assessment?

Drawing from successful implementation strategies in heart failure, Dr. Desai argues for a paradigm shift in CKD care toward simultaneous initiation of the "four pillars" of therapy. This approach moves away from the traditional model of maximizing one drug before adding another, instead prioritizing early, comprehensive coverage to capture synergistic benefits across the cardiorenal metabolic spectrum. The experts note that because these therapies often target the same high-risk patient population—those with obesity, diabetes, and hypertension—clinicians have a unique opportunity to simplify complex regimens into a core group of multi-organ protective agents.

The discussion also details the logistical requirements of a follow-up visit, which must balance disease monitoring with medication onboarding. Dr. Beavers outlines a dual-track monitoring system: tracking eGFR and uACR progression according to the KDIGO heat map's risk levels, while simultaneously managing the aggressive monthly titration schedules required for newer agents like GLP-1 receptor agonists. The panel concludes that while the initial onboarding phase requires frequent assessment (often within one month of starting therapy), the predictable response of biomarkers like uACR provides a reliable metric for clinicians to gauge treatment success and ensure long-term stability.

Our next episode, ‘Clinical and Biomarker Signals for Escalating Therapy in High-Risk CKD,’ further explores chronic kidney disease, highlighting the transition of uACR from a diagnostic tool to a responsive biomarker, emphasizing its value in providing patients with tangible evidence of treatment success. They highlight that achieving at least a 30% reduction in uACR is a key clinical goal that not only confirms renal protection but also serves as a motivator for long-term adherence to complex, individualized therapy regimens.